Trials / Completed
CompletedNCT00168324
A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 599 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of macular edema associated with retinal vein occlusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 700 µg Dexamethasone | 700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180. |
| DRUG | 350 µg Dexamethasone | 350 µg Dexamethasone intravitreal implant administered on Day 0. |
| OTHER | Sham Injection | Sham injection on Day 0. |
Timeline
- Start date
- 2004-10-01
- Primary completion
- 2008-03-01
- Completion
- 2008-10-01
- First posted
- 2005-09-15
- Last updated
- 2019-04-23
- Results posted
- 2009-08-26
Locations
13 sites across 13 countries: United States, Australia, Austria, Canada, Czechia, France, Germany, Israel, Mexico, Philippines, Portugal, South Africa, Taiwan
Source: ClinicalTrials.gov record NCT00168324. Inclusion in this directory is not an endorsement.